These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 29623098)

  • 21. Diminished cholesterol efflux mediated by HDL and coronary artery disease in young male anabolic androgenic steroid users.
    Souza FR; Dos Santos MR; Porello RA; Fonseca GWPD; Sayegh ALC; Lima TP; Ferreira FD; Oliveira TF; Yonamine M; Takayama L; Pereira RMR; Negrão CE; Passarelli M; Rochitte CE; Alves MJNN
    Atherosclerosis; 2019 Apr; 283():100-105. PubMed ID: 30826541
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cholesterol Efflux Capacity and Its Association With Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis.
    Lee JJ; Chi G; Fitzgerald C; Kazmi SHA; Kalayci A; Korjian S; Duffy D; Shaunik A; Kingwell B; Yeh RW; Bhatt DL; Gibson CM
    Front Cardiovasc Med; 2021; 8():774418. PubMed ID: 34966797
    [No Abstract]   [Full Text] [Related]  

  • 23. Modulation of cholesterol efflux capacity in patients with myocardial infarction.
    Silvain J; Kerneis M; Guerin M; Montalescot G
    Curr Opin Cardiol; 2019 Nov; 34(6):714-720. PubMed ID: 31464772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease.
    Abdullah SM; Defina LF; Leonard D; Barlow CE; Radford NB; Willis BL; Rohatgi A; McGuire DK; de Lemos JA; Grundy SM; Berry JD; Khera A
    Circulation; 2018 Nov; 138(21):2315-2325. PubMed ID: 30571575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of Correlation of Plasma HDL With Fecal Cholesterol and Plasma Cholesterol Efflux Capacity Suggests Importance of HDL Functionality in Attenuation of Atherosclerosis.
    Srivastava N; Cefalu AB; Averna M; Srivastava RAK
    Front Physiol; 2018; 9():1222. PubMed ID: 30271349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations between High-Density Lipoprotein Functionality and Major Adverse Cardiovascular Events in Patients Who Have Undergone Coronary Computed Tomography Angiography.
    Inoue H; Shiga Y; Norimatsu K; Tashiro K; Futami M; Suematsu Y; Sugihara M; Nishikawa H; Katsuda Y; Miura SI
    J Clin Med; 2021 May; 10(11):. PubMed ID: 34070835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads.
    Horiuchi Y; Ohkawa R; Lai SJ; Shimano S; Hagihara M; Tohda S; Kameda T; Tozuka M
    Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30867253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis.
    Fadaei R; Poustchi H; Meshkani R; Moradi N; Golmohammadi T; Merat S
    Sci Rep; 2018 Aug; 8(1):11691. PubMed ID: 30076407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The beneficial effects of raising high-density lipoprotein cholesterol depends upon achieved levels of low-density lipoprotein cholesterol during statin therapy: Implications for coronary atheroma progression and cardiovascular events.
    Puri R; Nissen SE; Shao M; Kataoka Y; Uno K; Kapadia SR; Tuzcu EM; Nicholls SJ
    Eur J Prev Cardiol; 2016 Mar; 23(5):474-85. PubMed ID: 25691546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HDL cholesterol efflux capacity in rheumatoid arthritis patients: contributing factors and relationship with subclinical atherosclerosis.
    Tejera-Segura B; Macía-Díaz M; Machado JD; de Vera-González A; García-Dopico JA; Olmos JM; Hernández JL; Díaz-González F; González-Gay MA; Ferraz-Amaro I
    Arthritis Res Ther; 2017 May; 19(1):113. PubMed ID: 28569219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-density lipoprotein levels and risk of cardiovascular events: a review.
    Mureddu GF; Brandimarte F; De Luca L
    J Cardiovasc Med (Hagerstown); 2012 Sep; 13(9):575-86. PubMed ID: 21986488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of cholesterol uptake capacity, a novel indicator for HDL functionality, and coronary plaque properties: An optical coherence tomography-based observational study.
    Oshita T; Toh R; Nagano Y; Kuroda K; Nagasawa Y; Harada A; Murakami K; Kiriyama M; Yoshikawa K; Miwa K; Kubo T; Iino T; Nagao M; Irino Y; Hara T; Shinohara M; Otake H; Shinke T; Nakajima K; Ishida T; Hirata KI
    Clin Chim Acta; 2020 Apr; 503():136-144. PubMed ID: 31972150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
    Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
    J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A commentary on the paper, 'Development and validation of a novel automatable assay for cholesterol efflux capacity'.
    Bhale AS; Venkataraman K
    Biosci Rep; 2023 Jun; 43(6):. PubMed ID: 37199509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging strategies and agents to lower cardiovascular risk by increasing high density lipoprotein cholesterol levels.
    Greenfeder S
    Curr Med Chem; 2009; 16(2):144-56. PubMed ID: 19149567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association Between Cholesterol Efflux Capacity and Atherosclerotic Cardiovascular Disease in Patients With Familial Hypercholesterolemia.
    Ogura M; Hori M; Harada-Shiba M
    Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):181-8. PubMed ID: 26543100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipoprotein(a), cardiovascular disease, and contemporary management.
    Jacobson TA
    Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol efflux and reverse cholesterol transport.
    Favari E; Chroni A; Tietge UJ; Zanotti I; Escolà-Gil JC; Bernini F
    Handb Exp Pharmacol; 2015; 224():181-206. PubMed ID: 25522988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.